Coiled Thera Regulatory News (COIL)

7 May 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Attendance at Endless Frontier Labs 2026

Coiled Therapeutics to Showcase AO-252 at Prestigious Endless Frontier Labs 2026 Event

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that it will be featured at the prestigious Endless Frontier Labs (EFL) Frontiers 2026 event today in New York City. The Company's Chief Technology Officer, Chaemin Lim, will present in the Oncology Diagnostics & Targeted Therapies block, a key segment of the event's Life Sciences track.

Based at the NYU Stern School of Business, Endless Frontier Labs is a leading non-profit accelerator programme for commercialising science and deep-tech companies. Coiled Therapeutics was selected to participate in the highly competitive nine-month EFL programme, with only 5% of applicants successfully graduating, which is designed to help early-stage science and technology-based companies accelerate their development. The programme has an excellent track record of helping to accelerate growth amongst its alumni companies. 

The Company's admission to the programme follows the release of highly encouraging clinical trial data for its lead asset, AO-252, a first-in-class TACC3 inhibitor. Recent updates from the trial demonstrated an 80% Clinical Benefit Rate in the twice daily cohort, a significant signal of efficacy in a heavily pre-treated patient population.

Participation in the programme provides a significant endorsement of Coiled Therapeutics' technology and its potential to make a major impact in the field of oncology. The programme offers invaluable mentorship from industry experts, access to a network of potential investors, and business development support from NYU Stern School of Business.

CEO of Coiled Therapeutics, Sridhar Vempati said: "Presenting at Endless Frontier Labs allows us to showcase our technology and to connect with an excellent network of investors and industry experts who recognise the potential of our science. We are eager to build on our recent clinical momentum and share our vision for AO-252 to be a much-needed treatment for patients who have exhausted all other options."

The Frontiers 2026 event is the culmination of the EFL programme, where the latest cohort of companies present their innovations to an audience of investors and industry leaders. 

-Ends-

Enquiries:

About Endless Frontier Labs: Endless Frontier Labs is a nine-month programme at the NYU Stern School of Business for early-stage science and technology-based startups. The programme is designed to help early-stage companies transform their scientific and technological ideas into commercially scalable companies. Companies are advised by experienced entrepreneurs, investors, and technical mentors, with a focus on achieving individualised business goals. The Life Sciences track at EFL is specifically for companies focused on complex problems in biology, chemistry, and related fields with applications in therapeutics, drug discovery, diagnostics, and other health-focused verticals. EFL is a non-profit organisation and does not take equity or charge fees. https://endlessfrontierlabs.com/

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com